logo-loader
viewMaxCyte Inc

MaxCyte hires Asian distributors to meet demand

Bio Laboratories Pte Ltd will be the distributor of the systems in Singapore

cells.jpg
Tom Ross, executive vice-president for global sales, said: "Researchers in Asia continue to play an increasingly important role in the discovery and development of new biologics and small molecule drugs”,

Cell engineering specialist MaxCyte Inc (LON:MXCT) has appointed distributors in the key markets of Japan and Singapore for its instruments business, it revealed.

Tom Ross, executive vice-president for global sales, said: "Researchers in Asia continue to play an increasingly important role in the discovery and development of new biologics and small molecule drugs, and thus Asia is a focal market for MaxCyte's instruments business."

Kiko Tech Co, established in 1974, will serve throughout Japan as the authorized distributor for the MaxCyte transfection systems for drug discovery and biomanufacturing.

Bio Laboratories Pte Ltd will be the distributor of the systems in Singapore.

Ross added: "Many leading Asian pharmaceutical companies already use the MaxCyte STX Scalable Transfection System.

"In addition, we are adding new staff, including a senior-level manager, to support our business in Asia."

The MaxCyte GT Flow Transfection System, the MaxCyte STX Scalable Transfection System, and the MaxCyte VLX Large Scale Transfection System enable the rapid development of transfected cells for a broad array of applications.

MaxCyte is also developing CARMA - its proprietary platform in immuno-oncology.

Shares eased 2.22% to 82.62p.

Quick facts: MaxCyte Inc

Price: 118.5 GBX

AIM:MXCT
Market: AIM
Market Cap: £68.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read